KRON Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	442 697
Gjennomsnittsvolum	376 179
Markedsverdi	60.10M
EPS	$0 ( 2024-03-20 )
Neste inntjeningsdato	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Olek Elizabeth A	Sell	7 368	Common Stock
2024-02-16	Olek Elizabeth A	Sell	0	Common Stock
2024-02-16	Olek Elizabeth A	Sell	89 120	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	145 795	Stock Option (Right to Buy)
2024-02-16	Olek Elizabeth A	Sell	87 500	Stock Option (Right to Buy)

INSIDER POWER
45.50
Last 97 transactions
Buy: 7 377 688 \| Sell: 1 665 671

Volum Korrelasjon

Lang: -0.19 (neutral)

Kort: -0.66 (moderate negative)

Signal:(63.835) Neutral

Kronos Bio, Inc. Korrelasjon

10 Mest positive korrelasjoner
VVOS	0.892
PASG	0.886
SRTS	0.876
SGBX	0.876
FREQ	0.863
ATHE	0.858
CNDT	0.852
FOSL	0.846
KOD	0.841
VNET	0.84

10 Mest negative korrelasjoner
TYHT	-0.846
VERX	-0.827
BLCT	-0.81
HSTM	-0.81
XOG	-0.806

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kronos Bio, Inc. Korrelasjon - Valuta/Råvare

0.60
( weak )

0.63
( weak )

0.00
( neutral )

0.19
( neutral )

Kronos Bio, Inc. Økonomi

Annual	2023
Omsetning:	$6.29M
Bruttogevinst:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2023
Omsetning:	$6.29M
Bruttogevinst:	$1.37M (21.82 %)
EPS:	$-1.950

FY	2022
Omsetning:	$0
Bruttogevinst:	$-4.46M (0.00 %)
EPS:	$-2.30

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.79

Financial Reports:

No articles found.

Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.